FDA requests removal of Opana ER for risks related to abuse

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm

Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

NBA;

It is an effective analgesic, but there are many safer effective analgesics.  There have been to many opiate deaths.  When will we learn that buprenorphine is safe & effective for pain relief?!

• Author
• Recent Posts

Dr. Raymond Oenbrink

Dr. Raymond Oenbrink DO is board certified by the American Osteopathic Board of Family Physicians (AOBFP) and the American Board of Addiction Medicine (ABAM). He specializes in complex and chronic illnesses such as Chronic Inflammatory Response Syndrome (CIRS).

Latest posts by Dr. Raymond Oenbrink (see all)

• COVID UPDATE: What is the truth? - 2022-11-08
• Pathologist Speaks Out About COVID Jab Effects - 2022-07-04
• A Massive Spike in Disability is Most Likely Due to a Wave of Vaccine Injuries - 2022-06-30